Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy
The DOI matches its Crossref record.
Abstract
Chemotherapy of solid tumors is presently largely ineffective at dosage levels that are compatible with survival of the patient. Here, it is argued that a condition of raised interstitial fluid pressure (IFP) that can be observed in many tumors is a major factor in preventing optimal access of systemically administered chemotherapeutic agents. Using prostaglandin E1‐methyl ester (PGE 1 ), which is known transiently to reduce IFP, it was shown that 5‐fluorouracil (5‐FU) caused significant growth inhibition on two experimental tumors in rats but only after administration of PGE 1 . Furthermore, timing experiments showed that only in the period in which IFP is reduced did 5‐FU have an antitumor effect. These experiments uniquely demonstrate a clear and, according to the starting hypothesis, logical, synergistic effect of PGE 1 and 5‐FU that offers hope for better treatment of many tumors in which raised IFP is likely to be inhibiting optimal results with water‐soluble cancer chemotherapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
“PGE 1 also increased the antitumour effect of 5-fluorouracil, but only when this drug was administered during the time IFP was lowere”
BackgroundSelf-citationDrug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288
Wiig, H., & Swartz, M. A. (2012) · Physiological Reviews · doi:10.1152/physrev.00037.2011 · Cited by 722
Mechanisms of Multidrug Resistance in Cancer
Gillet, J.-P., & Gottesman, M. M. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_4 · Cited by 685
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Alfarouk, K. O., Stock, C.-M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Bashir, A. H. H., Mohammed, O. Y., Elhassan, G. O., Harguindey, S., et al. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0221-1 · Cited by 665
Improving drug delivery to solid tumors: Priming the tumor microenvironment
Khawar, I. A., Kim, J. H., & Kuh, H.-J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.018 · Cited by 533
Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression
Niland, S., Riscanevo, A. X., & Eble, J. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010146 · Cited by 503
Analysis on the current status of targeted drug delivery to tumors
Kwon, I. K., Lee, S. C., Han, B., & Park, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.010 · Cited by 404
Cairns, R., Papandreou, I., & Denko, N. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0002 · Cited by 370
Mittelheisser, V., Gensbittel, V., Bonati, L., Li, W., Tang, L., & Goetz, J. G. (2024) · Nature Nanotechnology · doi:10.1038/s41565-023-01535-8 · Cited by 109
“This results in a subsequent imbalance of interstitial fluid pressure, further preventing efficient delivery of chemotherapeutic molecules to the tumour 23 .”
Hofmann, M., Guschel, M., Bernd, A., Bereiter-Hahn, J., Kaufmann, R., Tandi, C., Wiig, H., & Kippenberger, S. (2006) · Neoplasia · doi:10.1593/neo.05469 · Cited by 106
Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics
Ferretti, S., Allegrini, P. R., Becquet, M. M., & McSheehy, P. M. J. (2009) · Neoplasia · doi:10.1593/neo.09554 · Cited by 106
“Preclinically, this has been shown for dexamethasone [4], hydralazine [5], imatinib [6], PGE1 [7], and patupilone [8].”
BackgroundLee, S. W. L., Seager, R. J., Litvak, F., Spill, F., Sieow, J. L., Leong, P. H., Kumar, D., Tan, A. S. M., Wong, S. C., Adriani, G., et al. (2020) · Integrative Biology · doi:10.1093/intbio/zyaa007 · Cited by 60
Han, B., Qu, C., Park, K., Konieczny, S. F., & Korc, M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.12.003 · Cited by 53
Moen, I., Tronstad, K. J., Kolmannskog, O., Salvesen, G. S., Reed, R. K., & Stuhr, L. E. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-446 · Cited by 49
Self-citation
Metadata
- Authors
- Salnikov, A. V., Iversen, V. V., Koisti, M., Sundberg, C., Johansson, L., Stuhr, L. B., Sjöquist, M., Ahlström, H., Reed, R. K., & Rubin, K.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2003-07-18
- Volume
- 17
- Issue
- 12
- Pages
- 1756-1758
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2072497851
- Cited by
- 116
- References
- 0
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.